The dilutive financing provides near-term liquidity but adds share overhang; the dual-sourcing strategy adds optionality but delays NDA resubmission. Monitor the Aug 6 closing and any news on the contract manufacturers' progress.
Price Chart
Executive Summary
Grace Therapeutics announced a ~$10M private placement (4,761,904 shares at $2.10/share) with new and existing fundamental investors, expected to close August 6, 2026. Net proceeds will fund manufacturing and regulatory work for GTx-104, with a dual-source manufacturing strategy underway. The company expects cash runway through end of 2028.
Key Financial Metrics
Key Facts
- Private placement raising approximately $10M in gross proceeds.
- Issuing 4,761,904 shares at $2.10 per share (at-the-market under Nasdaq rules).
- Expected to close August 6, 2026.
- Net proceeds plus existing cash hoped to extend runway to end of calendar 2028.
- Dual-source manufacturing strategy initiated: technology transfer to a second U.S.-based contract manufacturer underway, with NDA resubmission timing dependent on manufacturing readiness.
Financial Impact
$10 million gross proceeds from private placement; dilution of 4,761,904 shares.
Risk Factors
- Dilution of 4.76M shares outstanding (approximately 17% based on pre-deal shares; exact dilution not computable without prior count).
- NDA resubmission timeline uncertain; manufacturing readiness (12 months stability data) may be the gating factor.
- CRL still unresolved: FDA has not approved GTx-104; additional non-clinical studies may be needed.
- Cash runway extension relies on proceeds plus existing cash; may need further capital if delays occur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3338997 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Insider Cluster | $2.26 $2.22 | ▼ −1.77% | ▼ −2.62% | $1.93 (−14.60%) |
Aug 13, 2026 10w ago | 8-K | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 13, 2026 10w ago | Press Release | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 4, 2026 11w ago | Press Release | $2.14 $2.12 | ▼ −0.93% | ▼ −0.77% | $1.93 (−9.81%) |
Jul 28, 2026 12w ago | 8-K | $2.25 $2.08 | ▼ −7.56% | ▼ −6.02% | $1.93 (−14.22%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▼ −5.04% | ▼ −4.73% | $1.93 (−18.91%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 18, 2026 18w ago | Press Release | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 5, 2026 20w ago | 8-K | $2.30 $2.33 | ▲ +1.30% | ▲ +1.60% | $1.93 (−16.09%) |
Apr 27, 2026 26w ago | 8-K | $2.16 $2.10 | ▲ +2.78% | ▲ +2.29% | $1.93 (+10.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers